Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 5/20 | 0.74 |
| ▸ | DGKA | P23743 | 1/20 | 0.57 |
| ▸ | KDM5A | P29375 | 4/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | PAM | P19021 | 2/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.44 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KDM5C | P41229 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18350966 | 0.99 | DNM1 (0.72) | DNM1DGKAKDM5APRSS1PRSS2 | |
| SCHEMBL14157454 | 0.97 | DNM1 (0.74) | DNM1DGKAKDM5APRSS1PRSS2 | |
| SCHEMBL26054432 | 0.96 | DNM1 (0.72) | DNM1DGKAKDM5APRSS1PRSS2 | |
| SCHEMBL18335339 | 0.96 | DNM1 (0.72) | DNM1DGKAKDM5APRSS1PRSS2 | |
| SCHEMBL18350965 | 0.94 | DNM1 (0.74) | DNM1DGKAKDM5APRSS1PRSS2 | |
| SCHEMBL21027726 | 0.93 | DNM1 (0.64) | DNM1DGKAKDM5APRSS1PRSS2 | |
| SCHEMBL14157552 | 0.93 | DNM1 (0.77) | DNM1DGKAKDM5APRSS1PRSS2 | |
| SCHEMBL21026909 | 0.92 | DNM1 (0.63) | DNM1DGKAKDM5APRSS1PRSS2 | |
| SCHEMBL17586403 | 0.92 | DNM1 (0.63) | DNM1DGKAMAPT | |
| SCHEMBL15027024 | 0.92 | DNM1 (0.66) | DNM1DGKAKDM5APRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2858974-B9 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORP (JP) | 2022-07-20 | — | — | EP | disclosed |
| EP-3489220-B9 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORP (JP) | 2021-11-10 | — | — | EP | disclosed |
| EP-3489220-B9 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORP (JP) | 2021-11-10 | — | — | EP | disclosed |
| EP-3489220-B1 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORP (JP) | 2021-08-18 | — | — | EP | disclosed |
| EP-3489220-B1 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORP (JP) | 2021-08-18 | — | — | EP | disclosed |
| US-20200085957-A1 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORPORATION (JP) | 2020-03-19 | — | — | US | disclosed |
| US-10441659-B2 | Lipids for therapeutic agent delivery formulations | NITTO DENKO CORPORATION (JP) | 2019-10-15 | — | — | US | disclosed |
| US-10441659-B2 | Lipids for therapeutic agent delivery formulations | NITTO DENKO CORPORATION (JP) | 2019-10-15 | — | — | US | disclosed |
| US-20190275158-A1 | SKIN FIBROSIS TREATMENT AGENT | NITTO DENKO CORP (JP) | 2019-09-12 | — | — | US | disclosed |
| EP-3536343-A1 | SKIN FIBROSIS TREATMENT AGENT | Nitto Denko Corporation (JP) | 2019-09-11 | — | — | EP | disclosed |
| EP-3489220-A1 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | Nitto Denko Corporation (JP) | 2019-05-29 | — | — | EP | disclosed |
| EP-3489220-A1 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | Nitto Denko Corporation (JP) | 2019-05-29 | — | — | EP | disclosed |
| EP-2858974-B1 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORP (JP) | 2018-10-17 | — | — | EP | disclosed |
| US-9976142-B2 | Targeting molecule and a use thereof | NITTO DENKO CORPORATION (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9976142-B2 | Targeting molecule and a use thereof | NITTO DENKO CORPORATION (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20170022500-A1 | A TARGETING MOLECULE AND A USE THEREOF | NITTO DENKO CORPORATION (JP) | 2017-01-26 | — | — | US | disclosed |
| US-20170022500-A1 | A TARGETING MOLECULE AND A USE THEREOF | NITTO DENKO CORPORATION (JP) | 2017-01-26 | — | — | US | disclosed |
| US-9308267-B2 | Lipids for therapeutic agent delivery formulations | NITTO DENKO CORPORATION (JP) | 2016-04-12 | — | — | US | disclosed |
| US-9308267-B2 | Lipids for therapeutic agent delivery formulations | NITTO DENKO CORPORATION (JP) | 2016-04-12 | — | — | US | disclosed |
| US-20160074514-A1 | Lipids for Therapeutic Agent Delivery Formulations | NITTO DENKO CORPORATION (JP) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022500-A1 | A TARGETING MOLECULE AND A USE THEREOF | STRA6, RBP1, FABP1 | DNM1 2752/4885DGKA 3550/4885KDM5A 2466/4885 |
| US-20160074514-A1 | Lipids for Therapeutic Agent Delivery Formulations | LIPA, SGMS2, SGMS1 | DNM1 235/4885DGKA 377/4885KDM5A 4875/4885 |
| US-20200085957-A1 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | LIPA, SGMS2, SGMS1 | DNM1 235/4885DGKA 377/4885KDM5A 4875/4885 |
| US-10441659-B2 | Lipids for therapeutic agent delivery formulations | LIPA, SGMS2, SGMS1 | DNM1 235/4885DGKA 377/4885KDM5A 4875/4885 |
| US-20190275158-A1 | SKIN FIBROSIS TREATMENT AGENT | COL1A1, COLGALT1, COL14A1 | DNM1 4615/4885DGKA 901/4885KDM5A 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.